- Home
- RLYB vs RTSN Comparison
RLYB vs RTSN Comparison
Compare RLYB & RTSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | RTSN |
|---|---|---|
| Founded | 2018 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2M | 96.2M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | RLYB | RTSN |
|---|---|---|
| Price | $15.62 | $12.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 24.4K | ★ 108.1K |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.64 | N/A |
| Revenue | ★ $858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.80 | ★ N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.56 | $10.31 |
| 52 Week High | $32.54 | $18.64 |
Technical Indicators
Market Signals| Indicator | RLYB | RTSN |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 50.82 |
| Support Level | $7.93 | $10.58 |
| Resistance Level | $16.89 | $12.93 |
| Average True Range (ATR) | 1.79 | 1.50 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 2.78 | 30.50 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.